Novo Nordisk’s Wegovy gets UK approval for use to lower heart risks
(Reuters) -Novo Nordisk’s weight-loss drug Wegovy secured the UK regulator’s approval for its use to reduce the risk of serious heart problems or strokes in overweight and obese adults, the agency said on Tuesday. Approval from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) follows a similar nod from the U.S. Food and Drug Administration …
Novo Nordisk’s Wegovy gets UK approval for use to lower heart risks Read More »